Our analysis identified high levels of MUC13 to be a marker of sensitivity to the BTSA1.2 and Navitoclax combination, suggesting that this combination therapy could be beneficial for cancer patients with high levels of MUC13. Interestingly, MUC13 has been proposed as a marker of poor prognosis in colorectal tumors60, supporting our findings for combined targeting of BAX and BCL-XL in resistant colorectal tumors. This evidence concerns the gene BAX and cancer.